... with one "weak yes vote". FDA will see this almost as an 8-7 vote which is very weak. I predict that the FDA will require additional data on tumor growth and fat buildup. This would have sailed through had there not been AEGR's drug the day before , which has a better safety profile and more efficacy. Any endocrinoligist prescribing a med will choose lomitapide first, Mipo second. Getting FDA approval on Mipo is by no means a slam dunk at this point. AEGR will be at 25 by Monday.
from adam feuerstein on his live blog of today's session:
the overall message from the votes and the commentary from the past 2 days is that $AEGR is in a better position than $ISIS and $SNY. more comfort with lomi than mipo